By Hendra Lukman 
The H5N1 avian influenza virus, commonly known as bird flu, has become a growing concern in the United States since its initial identification in 2014. What began as an infection primarily affecting wild bird populations has demonstrated a concerning capacity to spread beyond its natural hosts, impacting farm animals, including dairy cows, and, crucially, infecting humans. The U.S. has reported over 70 human cases of H5N1 since 2022, with two fatalities underscoring the virus’s potential severity. As H5N1 continues its widespread circulation among animal populations, scientists are increasingly vigilant about its potential to evolve. This evolutionary capacity raises the specter of a future pandemic, driven by a strain of the virus that could become more adept at transmitting efficiently between people.
In response to this escalating threat, researchers at Washington University School of Medicine in St. Louis have developed an innovative intranasal vaccine designed to deliver potent immunity directly to the respiratory tract. This novel approach bypasses the traditional intramuscular injection, aiming to establish a more robust defense at the initial sites of viral entry. Early studies conducted in laboratory settings with hamsters and mice have yielded promising results, demonstrating that the intranasal vaccine elicits strong immune responses and effectively prevents H5N1 infection following exposure.
A significant hurdle in vaccine development, particularly for influenza viruses, is the potential for pre-existing immunity from prior seasonal flu infections or vaccinations to diminish the effectiveness of new vaccines. This phenomenon, known as original antigenic sin or imprinting, can lead to suboptimal immune responses. However, the WashU Medicine team’s research indicates that their intranasal H5N1 vaccine maintains its efficacy even in animals that have already developed immunity to other influenza strains, suggesting a critical advantage for widespread human application. The detailed findings of this research were published on January 30th in the esteemed journal Cell Reports Medicine.
A Critical Moment for Pandemic Preparedness
The recent spillover of H5N1 into dairy cattle herds across the United States marked a pivotal moment, amplifying concerns about the virus’s adaptability and its potential to trigger a pandemic. Jacco Boon, PhD, a professor in the WashU Medicine John T. Milliken Department of Medicine and co-senior author of the study, emphasized the urgency of the situation. "This particular version of bird flu has been around for some time, but the unique and totally unexpected event where it jumped across species into dairy cows in the United States was a clear sign that we should prepare for the event that a pandemic may occur," Dr. Boon stated. He further elaborated on the advantages of their nasal vaccine, highlighting its capacity to protect the upper airway, the primary site of initial infection for respiratory viruses. "Our vaccine to the nose and upper airway — not the shot-in-the-arm vaccine people are used to — can protect against upper respiratory infection as well as severe disease. This could provide better protection against transmission because it protects against infection in the first place."
Advancing Avian Influenza Vaccine Technology
While an existing bird flu vaccine is available, it was developed using older strains of the virus and may not offer optimal protection against the current circulating H5N1 variants. Furthermore, its availability has been limited. To address these shortcomings, Dr. Boon and his colleagues leveraged cutting-edge nasal vaccine technology that had been previously pioneered at WashU Medicine by study co-authors Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, and David T. Curiel, MD, PhD, a professor of radiation oncology. This platform has already demonstrated success, forming the basis of a COVID-19 vaccine that has been available in India since 2022 and received approval for clinical testing in the U.S. last year. This existing success with a similar platform provides a strong foundation for the development of an effective H5N1 nasal vaccine.
Engineering an Immune Response Tailored to the Virus
The efficacy of any vaccine hinges on the immune system’s ability to swiftly recognize and neutralize the target pathogen. To achieve this, Dr. Boon and co-author Eva-Maria Strauch, PhD, an associate professor of medicine specializing in antivirals and protein design, meticulously selected proteins from H5N1 strains known to infect humans. By identifying and capitalizing on conserved features within these viral proteins, they engineered an optimized antigen – the critical component of a vaccine that triggers an immune response. This engineered antigen was then integrated into a harmless, non-replicating adenovirus, which serves as a sophisticated delivery vehicle for the vaccine. This strategic combination of antigen design and adenovirus delivery closely mirrors the successful methodology employed in the development of the COVID-19 nasal vaccine.
Robust Protection Demonstrated in Animal Models
The efficacy of the intranasal H5N1 vaccine was rigorously tested in animal models. In studies involving hamsters and mice, researchers observed a remarkable level of protection, with near-complete prevention of H5N1 infection following vaccination. As anticipated, pre-existing seasonal flu vaccines provided minimal defense against the avian influenza virus. Crucially, in both animal models, the intranasal spray vaccine conferred superior protection compared to the same vaccine administered via a traditional intramuscular injection. The vaccine’s resilience was further highlighted by its high effectiveness even when administered at low doses and subsequently challenged with high viral loads, underscoring its potential for robust protection in real-world scenarios.
Disrupting Transmission at the Source: Nose and Lungs
The direct delivery of the vaccine to the nasal passages has a profound impact on the immune response, generating potent immunity throughout the respiratory tract, with particularly high activity concentrated in the nasal passages and lungs. Dr. Boon explained the significant advantage this offers over injectable vaccines. "We’ve shown that this nasal vaccine delivery platform we conceived, designed and conducted initial testing on at WashU Medicine can prevent H5N1 infection from taking hold in the nose and lungs," stated Dr. Diamond, a co-senior author of the study. "Delivering vaccine directly to the upper airway where you most need protection from respiratory infection could disrupt the cycle of infection and transmission. That’s crucial to slowing the spread of infection for H5N1 as well as other flu strains and respiratory infections." By blocking the virus at its initial points of entry, the nasal vaccine has the potential to not only reduce the severity of illness but also significantly curb the spread of infection from person to person.
Overcoming Pre-existing Immunity Challenges
A critical aspect of the study involved assessing the impact of pre-existing immunity from prior influenza infections or vaccinations on the H5N1 nasal vaccine’s performance. The researchers found that the intranasal vaccine continued to provide robust protection even in the presence of pre-existing flu immunity. This is a vital consideration for the widespread deployment of the vaccine, given that the vast majority of the population, with the exception of young children, has developed immune memory from past influenza exposures. This finding suggests that the nasal vaccine may offer a more consistent and effective shield across a broader demographic.
The Road Ahead: Further Development and Clinical Translation
The research team is committed to advancing the development of this promising nasal vaccine. Their next steps include conducting further comprehensive studies in animal models and utilizing organoid systems that accurately mimic human immune tissue to refine the vaccine’s design and assess its broader immunological effects. Furthermore, they are actively working on updated versions of the vaccine. These enhanced formulations aim to further minimize any potential interference from pre-existing seasonal flu immunity and to amplify antiviral responses, ensuring the highest possible level of protection against H5N1.
The development of this intranasal vaccine was supported by grants from the Cooperative Center for Human Immunology (U19AI181103) and the Center for Research on Structural Biology of Infectious Diseases (75N93022C00035). The Boon laboratory has received funding from Novavax Inc. for influenza virus vaccine development and unrelated funding from AbbVie Inc. Dr. Diamond serves as a consultant for or is on the Scientific Advisory Board of Inbios, IntegerBio, Akagera Medicines, GlaxoSmithKline, Merck, and Moderna. The Diamond laboratory has also received unrelated funding support through sponsored research agreements from Moderna. These disclosures highlight the collaborative and multifaceted nature of advanced vaccine research, involving both academic institutions and industry partners.
Broader Implications and the Path to Pandemic Resilience
The emergence and sustained circulation of H5N1 avian influenza in the U.S. and globally represent a significant public health challenge. The virus’s demonstrated ability to jump from birds to mammals, and subsequently to humans, underscores the complex interplay between animal and human health in the context of infectious diseases. The recent outbreak in dairy cattle, for instance, involved a scale of animal involvement and interspecies transmission not previously observed with H5N1 in the U.S., prompting intensified surveillance and research efforts.
The implications of this research extend beyond H5N1. The intranasal vaccine platform developed by the WashU Medicine team holds promise for addressing other respiratory pathogens. The ability to induce strong mucosal immunity in the upper and lower respiratory tracts could be a game-changer for controlling the spread of not only avian influenza but also seasonal influenza and potentially other emergent respiratory viruses. The COVID-19 pandemic served as a stark reminder of the global vulnerability to novel respiratory pathogens and the critical need for rapid development and deployment of effective countermeasures. This H5N1 nasal vaccine represents a significant stride towards building a more resilient global health infrastructure, equipped to respond swiftly and effectively to future pandemic threats. The ongoing research and development in this area are crucial for safeguarding public health and mitigating the devastating impact of novel infectious diseases.
